Calman Prussin, M.D., Joins Knopp Biosciences To Lead Clinical Development Of Dexpramipexole In Eosinophilic Asthma

PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC announced today that Calman Prussin, M.D., formerly a senior investigator in eosinophil-associated inflammatory diseases at the National Institutes of Health and the outgoing chair of the American Board of Allergy and Immunology, has joined Knopp to head clinical and translational medicine in immunology.

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.